Annexon director granted 175,000 stock options

Annexon, Inc. reported that director Mark S. Blumenkranz received a grant of 175,000 stock options on August 10, 2026.

Rhea-AI Filing Summary

Annexon, Inc. reported that director Mark S. Blumenkranz received a grant of 175,000 stock options on August 10, 2026. The options have an exercise price of $5.39 per share and expire on August 10, 2036. According to the vesting terms, 1/36 of the shares vest monthly starting from August 10, 2026, so all 175,000 underlying common shares are scheduled to be fully vested and exercisable on the third anniversary of that date, subject to his continuous service as a director.

Insider Trade Summary

Grant/Award: 175,000 shares

Grant/Award 1 txn

Insider Blumenkranz Mark S.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) F1	175,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 175,000 contracts (Direct)

Footnotes (1)

1. F1. 1/36th of the shares subject to the option vest on each monthly anniversary measured from August 10, 2026 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Vesting Commencement Date, subject to Reporting Person's continuous service as a director on each such vesting date.

Key Figures

Stock options granted: 175,000 options Exercise price: $5.39 per share Options expiration date: August 10, 2036 +2 more

5 metrics

Stock options granted 175,000 options Grant of Stock Option (Right to Buy) on August 10, 2026

Exercise price $5.39 per share Conversion or exercise price of the granted stock options

Options expiration date August 10, 2036 Expiration date of the Stock Option (Right to Buy)

Underlying common shares 175,000 shares Each option corresponds to one share of Annexon common stock

Vesting period 36 months 1/36 of the shares vest monthly from August 10, 2026 over three years

Key Terms

Stock Option (Right to Buy), Vesting Commencement Date, continuous service

3 terms

Stock Option (Right to Buy) financial

"security_title is reported as Stock Option (Right to Buy)"

Vesting Commencement Date financial

"measured from August 10, 2026 (the "Vesting Commencement Date")"

The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.

continuous service financial

"subject to Reporting Person's continuous service as a director"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Annexon (ANNX) director Mark S. Blumenkranz report in this Form 4?

Director Mark S. Blumenkranz reported receiving a grant of 175,000 stock options for Annexon, Inc. These options were awarded on August 10, 2026 and represent the right to buy Annexon common stock under specified terms and conditions.

How many stock options were granted to the Annexon (ANNX) director and at what exercise price?

The director was granted 175,000 stock options with an exercise price of $5.39 per share. Each option is a right to buy one share of Annexon common stock at that price once the option has vested and before expiration.

What is the vesting schedule for the 175,000 Annexon (ANNX) stock options?

The options vest in 36 equal monthly installments, with 1/36 of the shares vesting each month from August 10, 2026. All shares are expected to be fully vested and exercisable by the third anniversary, subject to continuous service as a director.

When do the newly granted Annexon (ANNX) stock options expire?

The granted stock options expire on August 10, 2036. After that expiration date, any unexercised portion of the 175,000 options can no longer be used to purchase Annexon common stock at the $5.39 exercise price.

What will Mark S. Blumenkranz’s holdings be after this Annexon (ANNX) option grant?

Following this grant, the Form 4 shows 175,000 derivative securities (stock options) held directly. These options are separate from any common stock holdings and represent rights to acquire Annexon common shares in the future, subject to vesting and exercise.

Is the Annexon (ANNX) director’s option grant under a Rule 10b5-1 trading plan?

The filing’s Rule 10b5-1 checkbox is not marked as affirmative. The transaction is reported as a grant/award acquisition of options rather than an open-market trade executed under a pre-arranged Rule 10b5-1 trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/12/2026 - 06:11 PM Accepted by SEC EDGAR 08/12/2026 - 06:10 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Blumenkranz Mark S.

(Last) (First) (Middle)

C/O ANNEXON, INC.

1400 SIERRA POINT PKWY, BLDG C, STE 200

(Street)

BRISBANE CALIFORNIA 94005

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Annexon, Inc. [ ANNX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$5.39	08/10/2026		A		175,000		(1)	08/10/2036	Common Stock	175,000	$0	175,000	D

Explanation of Responses:

1. 1/36th of the shares subject to the option vest on each monthly anniversary measured from August 10, 2026 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Vesting Commencement Date, subject to Reporting Person's continuous service as a director on each such vesting date.

	/s/ Jennifer Lew, Attorney-in-Fact	08/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)